Key facts
- Notable investors include IBK Changgong, Altolan Ventures, Daedeok Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Lysin Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lysin Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lysin Bio
Devloper of antibiotics intended to provide bio-antibiotics to treat super bacteria. The company develops protein medicine based on gene recombinant technology, fermentation techniques, target material separating and purifying technology and a range of biotechnology, enabling patients to receive the best drugs to prevent bacteria.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2020
- Website
- lysinbio.com/
- Ownership
- Privately Held (backing)
Lysin Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lysin Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lysin Bio in its N-PORT filings yet. We sweep new filings monthly.